Cognitive peptide comparison: Semax vs Selank vs DSIP

The three most-procured Russian-school cognitive research peptides, Semax, Selank, and DSIP, each occupy a distinct mechanistic niche despite shared geographic research lineage. Compounding pharmacies, research labs, and OEM brands serving cognitive-research customers commonly procure all three.

At a glance

Semax, the BDNF/ACTH-derived cognitive peptide

Semax is a synthetic heptapeptide derived from the central fragment of ACTH (4-10). The molecule has been studied since the 1980s for effects on BDNF expression, neuroprotection, working memory, and attention-related applications. It's approved in Russia as a prescription medication for cerebrovascular and cognitive indications.

Mechanism: The hypothesized primary mechanism involves indirect upregulation of BDNF expression in cortical and hippocampal neurons. Secondary effects include neuroprotection in oxidative-stress models. The mechanism distinction from Selank and DSIP is that Semax engages the neurotrophin-pathway (BDNF) signaling rather than GABAergic or sleep-architecture pathways.

Administration: Intranasal route dominates the published research because Semax is not blood-brain-barrier permeable when delivered systemically. The intranasal route bypasses the BBB through direct olfactory-nerve and trigeminal-nerve transport into the CNS.

Best for: BDNF-research workflows, cognitive-enhancement and cerebrovascular research models, neuroprotection studies in oxidative-stress contexts.

Selank, the Tuftsin-derived anxiolytic

Selank is a synthetic heptapeptide derived from the immunomodulatory tetrapeptide Tuftsin. Approved in Russia for generalized anxiety disorder, the molecule is studied for anxiolytic, cognitive, and mood-related effects.

Mechanism: The pharmacology involves modulation of GABAergic transmission and enkephalin metabolism. The mechanistic distinction from Semax is the anxiolytic-pathway focus rather than neurotrophin signaling. The mechanistic distinction from benzodiazepine anxiolytics is that Selank's GABAergic modulation does not appear to produce sedation, motor impairment, dependence, or withdrawal, the dose-limiting profile that constrains benzodiazepine clinical use.

Administration: Intranasal in published research (same BBB-permeability rationale as Semax).

Best for: Anxiolytic research, mood-stabilizing studies, non-benzodiazepine GABA-pathway pharmacology.

DSIP, the orphan-receptor sleep peptide

DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide originally isolated from rabbit cerebral venous blood during electrical stimulation of sleep-promoting brain regions. Unlike Semax and Selank, DSIP's precise receptor target remains unidentified, making it both mechanistically less well-characterized and an ongoing research target for that reason.

Mechanism: Hypothesized mechanisms include modulation of GABAergic transmission, indirect effects on melatonin/serotonin pathways, and direct or indirect interaction with adenosine receptor signaling in sleep-promoting brain regions. The orphan-receptor status is unusual for a peptide with reproducible behavioral effects across decades of literature.

Administration: Both subcutaneous and intranasal routes are used in published research.

Best for: Sleep-architecture research, stress-response and neuroendocrine effects studies, exploratory mechanism research on the still-uncharacterized DSIP receptor.

How to choose between the three

The selection logic maps cleanly onto the experimental question:

For BDNF / neurotrophin / cognitive-enhancement research: Semax is the appropriate choice. The BDNF-pathway focus distinguishes it from the GABAergic-mechanism-focused Selank and the orphan-receptor DSIP.

For anxiolytic / mood research where benzodiazepine alternatives are needed: Selank is the appropriate choice. The non-benzodiazepine GABAergic mechanism is the distinguishing feature, and the Russian clinical-approval pedigree provides translational evidence.

For sleep-architecture or stress-response research: DSIP is the appropriate choice. The orphan-receptor status leaves room for novel mechanism studies, and the sleep-pathway focus distinguishes it from the cognitive-enhancement (Semax) and anxiolytic (Selank) emphases.

For combined cognitive + anxiolytic research: Semax + Selank in parallel is the standard combination. The two peptides act through different mechanisms and can be administered concurrently in research protocols.

Salt form, stability, and analytical considerations

All three peptides ship as acetate salts at ≥99.0% HPLC purity. The standard analytical packet includes:

• HPLC purity with peak integration
• ESI mass spec confirming molecular weight
• Water content by Karl Fischer
• Counter-ion identification

Sequence verification by LC-MS/MS is available on request but is rarely the critical test for 7-9 residue peptides, mass-spec identity confirmation is generally sufficient at this length.

For in vivo research workflows, request the LAL endotoxin test (USP <85>) and USP <61>/<62> microbial limits as add-on testing at quote stage. The cognitive-research readouts (cytokine assays, behavioral testing in rodent models) are particularly sensitive to endotoxin contamination because of the overlap with innate-immune signaling.

DSIP-specific handling note: DSIP is exceptionally hygroscopic compared with most other short peptides. The lyophilizate absorbs ambient moisture rapidly when the vial is opened, minimize the time the vial is open in ambient air, reconstitute promptly after first opening, and consider storing partially-used vials under dry nitrogen if extended use is planned.

Regulatory considerations

Semax and Selank are both approved as prescription medications in Russia (Semax for cerebrovascular/cognitive indications, Selank for anxiety) but unapproved in the US, EU, UK, or other major Western markets. The Russian-school clinical evidence base is concentrated in Russian-language journals; Western peer-reviewed coverage is limited.

Semax is on the FDA July 2026 PCAC agenda for 503A bulks-list consideration with proposed indications of cerebral ischemia, migraine, and trigeminal neuralgia. If FDA accepts PCAC's recommendation, US compounding pharmacies could formulate patient-specific Semax preparations under 503A. Until the FDA acts, US compounding use is constrained by the current regulatory posture. See our 503A vs 503B guide for the compounding-pathway context.

DSIP is not on any current PCAC review and has no approved-drug status in any major jurisdiction. It is supplied as a research-use compound.

For procurement teams running cognitive research programs, the standard procurement combination is Semax + Selank as the cognitive/anxiolytic pair, plus DSIP for sleep-architecture work. See /for/research-lab for the broader research-lab procurement workflow.